SCHEMBL9514079

SCHEMBL9514079

CCOP(=O)(OCC)c1cc(C)ccc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.46
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
GAA P10253 1/20 0.37
NLRP3 Q96P20 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
LMNA P02545 2/20 0.35
HTT P42858 1/20 0.35
ALDH1A1 P00352 2/20 0.35
NPSR1 Q6W5P4 1/20 0.34
HCRTR1 O43613 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
TAS1R2 Q8TE23 1/20 0.34
USP2 O75604 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5029134 0.87 POLB (0.51) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL1723651 0.85 POLB (0.46) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL2315516 0.82 POLB (0.51) POLBMEN1KMT2ASMN1; SMN2GAA
SCHEMBL12229781 0.82 ALDH1A1 (0.44) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL18354482 0.82 POLB (0.44) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL1631353 0.82 POLB (0.44) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL13978736 0.81 ACHE (0.46) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL18354483 0.80 POLB (0.42) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL1630147 0.79 POLB (0.44) POLBMEN1KMT2AKDM4ESMN1; SMN2
SCHEMBL4402997 0.79 ALDH1A1 (0.37) MEN1KMT2ASMN1; SMN2GAACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2880041-B1 PROCESS FOR PREPARATION OF ARYL PHOSPHOROUS COMPOUNDS COUNCIL SCIENT IND RES (IN) 2018-10-10 EP disclosed
US-20180072672-A1 BIPYRIDYL COMPOUND JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2018-03-15 US disclosed
US-9908852-B2 Bipyridyl compound JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2018-03-06 US disclosed
US-20170001960-A1 BIPYRIDYL COMPOUND JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2017-01-05 US disclosed
US-9200018-B2 Process for preparation of aryl phosphorous compounds COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-12-01 US disclosed
US-9200018-B2 Process for preparation of aryl phosphorous compounds COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-12-01 US disclosed
US-9200018-B2 Process for preparation of aryl phosphorous compounds COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-12-01 US disclosed
US-20150210725-A1 PROCESS FOR PREPARATION OF ARYL PHOSPHOROUS COMPOUNDS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-07-30 US disclosed
US-20150210725-A1 PROCESS FOR PREPARATION OF ARYL PHOSPHOROUS COMPOUNDS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-07-30 US disclosed
US-20150210725-A1 PROCESS FOR PREPARATION OF ARYL PHOSPHOROUS COMPOUNDS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-07-30 US disclosed
US-8044091-B2 Phospho-indoles as HIV inhibitors IDENIX PHARMACEUTICALS, INC. (US) 2011-10-25 US disclosed
EP-1961757-B1 Phosphoindoles as HIV inhibitors IDENIX PHARMACEUTICALS INC (US) 2010-09-01 EP disclosed
US-20090163444-A1 PHOSPHO-INDOLES AS HIV INHIBITORS IDENIX PHARMACEUTICALS LLC 2009-06-25 US disclosed
US-20090163444-A1 PHOSPHO-INDOLES AS HIV INHIBITORS IDENIX PHARMACEUTICALS LLC 2009-06-25 US disclosed
US-7534809-B2 Phospho-indoles as HIV inhibitors IDENIX PHARMACEUTICALS, INC. (US) 2009-05-19 US disclosed
US-7534809-B2 Phospho-indoles as HIV inhibitors IDENIX PHARMACEUTICALS, INC. (US) 2009-05-19 US disclosed
EP-1961757-A1 Phosphoindoles as HIV inhibitors IDENIX Pharmaceuticals, Inc. (US) 2008-08-27 EP disclosed
EP-0313002-B1 Phenyl glycines for use in reducing neurotoxic injury SEARLE & CO (US) 1993-12-01 EP disclosed
US-4918064-A TREATMENT OF ANOXIA OR ISCHEMIA G. D. SEARLE & CO. (US) 1990-04-17 US disclosed
EP-0313002-A2 Phenyl glycines for use in reducing neurotoxic injury G.D. Searle & Co. (US) 1989-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170001960-A1 BIPYRIDYL COMPOUND CBR1, NR0B2, ERBB2 POLB 1822/4885MEN1 2687/4885KMT2A 2180/4885
US-20090163444-A1 PHOSPHO-INDOLES AS HIV INHIBITORS IDO1, PPP5C, INMT POLB 712/4885MEN1 3483/4885KMT2A 1767/4885
US-20180072672-A1 BIPYRIDYL COMPOUND CBR1, NR0B2, ERBB2 POLB 1822/4885MEN1 2687/4885KMT2A 2180/4885
US-20150210725-A1 PROCESS FOR PREPARATION OF ARYL PHOSPHOROUS COMPOUNDS PFAS, PAICS, INPP5B POLB 1492/4885MEN1 642/4885KMT2A 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.